MNKD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MannKind Corp (MNKD) is not a strong buy for a beginner, long-term investor at this time. While the company has some upcoming catalysts and a favorable risk/reward outlook according to some analysts, the financial performance, hedge fund selling trends, and lack of significant recent positive news or signals make it prudent to hold off on investing for now.
The technical indicators are neutral. The MACD is slightly positive, RSI is neutral at 49.242, and moving averages are converging. The stock is trading near its pivot point of 2.756, with resistance at 2.92 and support at 2.592. There is no clear bullish or bearish signal.
Developmental updates for MNKD-201 in IPF are also anticipated soon.
Significant risks include the potential displacement of Tyvaso DPI royalties by United Therapeutics' soft mist inhaler, which could impact future revenues. Hedge funds are selling heavily, and there is no recent positive news or congress trading data to support the stock.
In Q4 2025, revenue increased by 45.82% YoY to $111.96M, but net income dropped significantly to -$15.95M (-314.87% YoY), and EPS fell to -0.05 (-266.67% YoY). Gross margin also declined to 71.82%, down 6.81% YoY.
Analysts have lowered price targets, with the most recent targets ranging from $3.50 to $8. While some analysts maintain Buy or Outperform ratings, concerns about Tyvaso DPI royalties and competition from United Therapeutics' new device have led to reduced optimism.
